Grilled Cheese

ExploreLog inSign up
Terms of UsePrivacy PolicyCommunity StandardsHelpGet the app

Grilled Cheese is a product of Village Compute

Version devBuilt at: 2026-10-15 21:53:40 EDT

PhotosVideosAllPeople
LatestRanked
@yalecancer.bsky.socialOct 14, 2026, 7:09 PM

Research from @ncasasanta.bsky.social + @maryamlustberg.bsky.social shows #TP53 alterations were found in 53% of adv. #breastcancer, but the targetable Y220C mutation appeared in 1.1%. The data highlights limited eligibility of p53 therapies, supporting the study of comb. therapies.
bit.ly/4hKVUdl

@livinglfs.bsky.socialOct 9, 2026, 2:30 PM

#lifraumeni #lifraumenisyndrome #livinglfs #iamlivinglfs #lifraumenisyndromeawareness #p53 #tp53 #tp53gene #cancergenetics #geneticcancer #geneticmutation #rarediseases #cancerfighter #genetictesting #LLFS #mentalhealth #breastcancerawareness #breastcancerawarenessmonth

Photo, no description
@talhabadarmd.bsky.socialOct 4, 2026, 8:30 PM

Should we transplant #TP53-mutated MDS? Outcomes are poor, but poor ≠ futile. Selected patients can achieve durable survival after alloHCT. TP53 should trigger refinement, not automatic exclusion. Select carefully. Transplant deliberately. Prevent relapse aggressively.👇🏽

Photo, no description
@livinglfs.bsky.socialOct 2, 2026, 1:26 PM

#lifraumeni #lifraumenisyndrome #livinglfs #iamlivinglfs #lifraumenisyndromeawareness #p53 #tp53 #tp53gene #cancergenetics #geneticcancer #geneticmutation #rarediseases #cancerfighter #breastcancer #breastcancerawarenessmonth #breastcancer #feelitonthefirst

Photo, no description
@livinglfs.bsky.socialSep 29, 2026, 6:12 PM

#lifraumeni #lifraumenisyndrome #livinglfs #iamlivinglfs #lifraumenisyndromeawareness #p53 #tp53 #tp53gene #cancergenetics #geneticcancer #geneticmutation #rarediseases #cancerfighter #childhoodcancerawareness #childhoodcancerawarenessmonth #pediatriccancer #childhoodcancer #gogoldinseptember

Photo, no descriptionPhoto, no description
@octooxford.bsky.socialSep 24, 2026, 12:49 PM

MILI now has 90 participants randomised!

If you have #LiFraumeniSyndrome and are interested in the MILI trial – the Royal Marsden in London is taking out-of-area referrals.

To learn about the MILI trial and LFS, visit mili.octru.ox.ac.uk

#TP53 #LFS @oncology.ox.ac.uk @oxfordcancer.bsky.social

90 participants randomised - thank you to the fantastic NHS staff at all our sites! The Royal Marsden (London & Sutton) Manchester University Hospitals Western General (Edinburgh) University Hospitals Leicester University Hospitals Southampton Clinical Genetics Aberdeen Nottingham University Hospitals Cambridge University Hospitals Guy’s and St Thomas’ (London)
@octooxford.bsky.socialSep 17, 2026, 12:47 PM

Royal Marsden is accepting referrals for the MILI trial from across the UK - including the devolved nations.

To learn about the MILI trial and LFS, visit mili.octru.ox.ac.uk

#TP53 #LFS @oncology.ox.ac.uk @oxfordcancer.bsky.social

Royal Marsden is accepting referrals for the MILI trial from across the UK - including the devolved nations. To learn about the MILI trial and LFS, visit https://mili.octru.ox.ac.uk/
@octooxford.bsky.socialSep 10, 2026, 11:44 AM

The LFS UK 2026 conference is on Saturday 12th September in London!

Tickets are free and it’s open to people with LFS and family/friends, health-carers and researchers.

Organised by the George Pantziarka TP53 Trust:
www.tp53.co.uk

#TP53 #LFS @oncology.ox.ac.uk @oxfordcancer.bsky.social

LFS UK 2026 – supporting Li Fraumeni Syndrome families, promoting research, building community. Saturday 12th September, 10am-5pm. International Student House, 229 Great Portland Street, London, W1B 1PF Email: info@tp53.org Website: www.tp53.org The George Pantziarka TP53 Trust
@cancers-mdpi.bsky.socialSep 9, 2026, 8:35 AM

🎯Editor's Choice!
Management of Acute Myeloid #Leukemia: A Review
🧑‍⚕️by Chetan Jeurkar, Lana King et al. from @jeffersonuniv.bsky.social
📊 Cited 7 times
Full text➡️ www.mdpi.com/2072-6694/18...
#ALL #FLT3 #TP53

Figure 1. Schematic representation of the major molecular pathways driving leukemogenesis and targeted therapies in acute myeloid leukemia (AML). Black arrows indicate stimulation, red lines with stop bars indicate inhibition. (Left) In NPM1-mutated and KMT2A-rearranged AML, formation of the menin–KMT2A transcriptional complex leads to aberrant activation of HOX and MEIS1 genes, sustaining leukemic proliferation and differentiation arrest. Small-molecule menin inhibitors (e.g., revumenib, ziftomenib) disrupt this interaction and suppress oncogenic transcription. (Middle) In FLT3-mutated AML, internal tandem duplication (ITD) or tyrosine-kinase domain (TKD) mutations result in constitutive activation of FLT3 and downstream PI3K, RAS, and JAK signaling pathways, driving proliferation and survival. Targeted agents including type 1 inhibitors (midostaurin, gilteritinib) and type 2 inhibitors (quizartinib) block these pathways. (Right) In IDH-mutated AML, formation of the onco-metabolite 2-hydroxyglutarate (2HG) induces DNA hypermethylation and dependence on BCL2 survival related to cytochrome C oxidase inhibition, leading to AML.